国际标准期刊号: 2573-4555

传统医学和临床自然疗法

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • CAS 来源索引 (CASSI)
  • 谷歌学术
  • 夏尔巴·罗密欧
  • 打开 J 门
  • Genamics 期刊搜索
  • 参考搜索
  • 研究期刊索引目录 (DRJI)
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

The Use of Complementary and Alternative Medicine in Children with Type 1 Diabetes Mellitus

Nevin Uslu,  Meral Bayat

The use of complementary and alternative medicine has been increasing in recent years. Complementary and alternative medicine in pediatrics are generally used in children with chronic illness/disabilities. Type 1 Diabetes Mellitus is also one of these chronic diseases. In this study, information on the use of complementary and alternative medicine in children with Type 1 Diabetes Mellitus was presented using scientific evidences. An literature search using the key words, “complementary”, “alternative”, “complementary and alternative medicine”, “integrative medicine”, “children with Type 1 Diabetes Mellitus” was performed by internet search in November-December, 2017 using Google Scholar, Pubmed, Cochrane Library, Science Direct, Web of Science. Researches between 2007-2017 have been included. Descriptive, cross-sectional, randomized controlled, double blind placebo controlled between 2007-2017; child and parent based studies have been examined and 13 studies have been included in the study. Although the studies on the use of complementary and alternative medicine in children with Type 1 Diabetes Mellitus are limited, their use varies between 18% and 56%, their use is affected by sociodemographic characteristics of the children and their parents. It is observed that the most used complementary and alternative medicine in children with Type 1 Diabetes Mellitus are herbal therapies, vitamins/minerals, nutritional/dietary supplements, prayer/spirutual practices, homeopathy and acupuncture. Studies have shown in children that these treatments are not particularly effective at HbA1c levels, that there is limited evidence of benefit-injury assessment, and that children with Type 1 Diabetes Mellitus require further evidence-based clinical trials.